Literature DB >> 29727608

Medical Management of Functional Impairment in Peripheral Artery Disease: A Review.

Mary M McDermott1.   

Abstract

Lower extremity peripheral artery disease (PAD) now affects 200 million people worldwide and is a major cause of disability. Cilostazol is the only Federal Drug Administration approved medication for PAD-related ischemic symptoms that is recommended by clinical practice guidelines. Supervised treadmill exercise significantly improves treadmill walking performance in PAD. Recent evidence shows that home-based exercise interventions that include occasional medical center visits and incorporate behavioral change techniques also significantly improve walking endurance in PAD. Upper and lower extremity ergometry (cycling) also improve walking ability in PAD. A recent decision by the Center for Medicaid and Medicare Services to cover supervised exercise for people with symptomatic PAD will increase access to exercise for the large number of people disabled by PAD.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Claudication; Exercise; Peripheral artery disease; Physical functioning

Mesh:

Substances:

Year:  2018        PMID: 29727608      PMCID: PMC6690383          DOI: 10.1016/j.pcad.2018.03.007

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  3 in total

Review 1.  Treatment Strategies for the Claudicant.

Authors:  Keith Pereira
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

2.  Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate.

Authors:  Jonathan Golledge; Jenna Pinchbeck; Sophie E Rowbotham; Lisan Yip; Jason S Jenkins; Frank Quigley; Joseph V Moxon
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.996

Review 3.  Patients with Diabetes Complicated by Peripheral Artery Disease: the Current State of Knowledge on Physiotherapy Interventions.

Authors:  Katarzyna Hap; Karolina Biernat; Grzegorz Konieczny
Journal:  J Diabetes Res       Date:  2021-05-10       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.